

2

In re Application of: Alexei SHIR et al
Serial No.: 10/535,189
Filed: September 21, 2006
Office Action Mailing Date: December 27, 2007

Examiner: Terra C. Gibbs
Group Art Unit: 1635
Attorney Docket: 29770

In the specification:

Please amend the Paragraph beginning at **Page 20, line 29**, as follows:

"Covalent association of molecules such as the nucleic acid carrier, the targeting moiety, and the dsRNA molecule of the present invention may be achieved using any of various chemical and biological methods well known to the ordinarily skilled artisan. For general guidance regarding the practice of such chemical methods, refer, for example, to the extensive guidelines provided by The American Chemical Society (~~wwwdotchemistrydotorg/portal/chemistry~~<http://www.chemistry.org/portal/Chemistry>). One of ordinary skill in the art, such as, for example, a chemist, will possess the required expertise for practicing chemical techniques suitable for covalently associating molecules for practicing the present invention".

Please amend the Paragraph beginning at **Page 26, line 33**, as follows:

"Ample guidance regarding surface markers specifically overexpressed in diseases such as cancer, and antibodies specific for such surface markers is provided in the literature of the art (for example, refer to: A M Scott, C Renner. "Tumour Antigens Recognised by Antibodies." In: Encyclopedia of Life Sciences, Nature Publishing Group, Macmillan, London, UK, ~~wwwdotelsdotnet~~www.els.net, 2001)."

In re Application of: Alexei SHIR et al
Serial No.: 10/535,189
Filed: September 21, 2006
Office Action Mailing Date: December 27, 2007

Examiner: Terra C. Gibbs
Group Art Unit: 1635
Attorney Docket: 29770

Please amend the Paragraph beginning at Page 47, line 10, as follows:

"Reagents: Branched polyethylenimine (PEI) having an average molecular weight of 25 kDa as determined via light scattering (PEI₂₅) and Succinimidyl 3-(2-pyridyldithio)propionate (SPDP) were purchased from Sigma-Aldrich (Munich, Germany). N-hydroxysuccinimidyl polyethyleneglycol maleimide (NHS-PEG-MAL, molecular weight = 3.4 kDa) was obtained from Nektar Therapeutics (~~http://www.nektar.com~~) (www.dotnektardotcom). The compound NHS-PEG-MAL is used for conjugating moieties having a suitable reactive group to PEG. Recombinant mouse epidermal growth factor (EGF) was purchased from Pepro Tech EC Ltd. (London, UK)".